-
Arrhythmia Research Technology (ART; Fitchburg, Massachusetts) said its wholly owned subsidiary, Micron Products, has completed the purchase of substantially all of the operating assets of privately held New England Molders (NEMI; Shrewsbury, Massachusetts).
-
Arrow International (Reading, Pennsylvania) said last month that it plans to defer a U.S. clinical trial of its current iteration of the LionHeart Left Ventricular Assist System (LVAS) for a destination therapy indication, saying it prefers to see how the next generation of the device, which has a smaller battery and other system enhancements, fares in the European market, where it was approved via a CE mark last November.
-
Presenters revealed some stunning data in coronary and peripheral revascularization during a press conference on late-breaking trials at the American College of Cardiologys (ACC; Bethesda, Maryland) annual scientific sessions in early March. The presentations at the Ernest N. Morial Convention Center included results from the three iterations of the ARCHeR (Acculink for Revascularization of Carotids in High-Risk Patients) trial, which is focused on treatment of carotid artery disease.
-
Early detection and rapid treatment is one of the most effective strategies available to physicians for improving outcomes of patients with myocardial infarction. A variety of technologies are under development that are intended to improve the ability to detect a heart attack rapidly, while others are designed to help minimize the adverse consequences of an acute coronary event using novel modalities to support the heart or preserve heart tissue.
-
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies
Before Onset of SLE; Prevention of VTE with Ximelagatran; Combined
Levothyroxine Plus Liothyronine Compared to Levothyroxine Alone in
Primary Hypothyroidism; Specific Site Involvement in Fixed Drug
Eruption; Anticoagulation Therapy for Stroke Prevention in Patients
with Atrial Fibrillation
-
-
The field of hyperbaric medicine is an evolving specialty, and the scope and practice is fluid with new research. This article will give an explanation into the various approved indications, the basic science rationale, and the pathophysiolgy of why hyperbaric medicine works.
-
-
Fifty-one consecutive hepatitis c patients with neuropathy were evaluated to determine whether, and by what mechanism, cryoglobulinemia was associated with peripheral neuropathy.
-
Benbadis and associates reviewed the medication history of patients with EEG-confirmed idiopathic generalized epilepsy.
